Patients with typical cold urticaria should be screened for cold-induced anaphylaxis risks and prescribed adrenaline autoinjectors, according to a study published in Allergy.
“Intramuscular adrenaline is the first-line treatment for anaphylaxis, and a delay in its administration is a risk factor for anaphylaxis-related death,” Mojca Bizjak, MD, a dermatology and dermatological allergology specialist with the University Clinic of Respiratory and Allergic Diseases Golnik Slovenia, and Marcus Maurer, MD, professor of dermatology and allergy at Charité – Universitätsmedizin